Tysabri and PML: Recognizing Symptoms and the Need for Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Risk Assessment

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early symptoms like confusion, vision changes, or weakness is critical for timely intervention. The medical community has long studied how biologic therapies can shift from beneficial to harmful under specific conditions, and Tysabri's association with PML is a key example. This page reviews the symptoms, timing, and documentation of PML to help you understand monitoring strategies.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The prognosis for patients who develop PML while on Tysabri is generally poor, with the condition "usually lead[ing] to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This section examines the long-term outcome of PML after Tysabri exposure, drawing on evidence from the drug's prescribing information. The clinical presentation of PML in Tysabri-treated patients is variable, often mimicking multiple sclerosis relapses. Symptoms may include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The prescribing information emphasizes that "an MRI scan should be obtained prior to initiating therapy with Tysabri" to help differentiate subsequent MS symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be useful, though brain lesions at baseline are uncommon.

Mechanism and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is compounded by three identified risk factors: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further elevates that risk. Regarding the adequacy of warnings, the prescribing information includes a boxed warning that clearly states Tysabri "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also mandates that "Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). To mitigate risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which ensures patients are monitored and educated about PML.

Prognosis and Long-Term Outcomes

Prognosis-related considerations for affected patients are sobering. The boxed warning notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that even with prompt diagnosis and treatment discontinuation, outcomes are often poor. Long-term survivors may experience permanent neurological deficits, including cognitive impairment, motor dysfunction, and vision loss. The risk of PML does not end with drug cessation; the prescribing information warns that "PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, patients should continue to be monitored for at least six months after stopping Tysabri. The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML developed after a median of 120 weeks in MS patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported earlier, especially in patients with prior immunosuppressant use. The risk increases with cumulative exposure, particularly beyond two years of treatment. Once PML is suspected, immediate discontinuation of Tysabri is critical, but this does not guarantee a favorable outcome. The infection can progress even after drug withdrawal, and immune reconstitution inflammatory syndrome (IRIS) may complicate recovery. In summary, the long-term outcome of PML after Tysabri is grave, with high rates of death or severe disability. The prescribing information provides clear warnings and risk stratification, but the prognosis remains poor for affected patients. Clinicians must carefully weigh the benefits of Tysabri against the risk of PML, especially in patients with anti-JCV antibodies, prolonged therapy, or prior immunosuppressant use. Continuous monitoring and prompt action at the first sign of PML are essential, though they do not eliminate the risk of devastating outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for PML after Tysabri?

The long-term prognosis for PML after Tysabri is generally poor, with the condition usually leading to death or severe disability. Survivors often experience permanent neurological deficits such as cognitive impairment, motor dysfunction, and vision loss. Even with prompt diagnosis and treatment discontinuation, outcomes are often unfavorable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The three main risk factors are the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration further elevates that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can PML occur after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Therefore, patients should continue to be monitored for at least six months after stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.